TGF-β/Smad

DJ4 is an ATP-competitive inhibitor of ROCK1/2 and MRCKα/β, with IC₅₀ values of 5 nM and 50 nM for ROCK1 and ROCK2, and 10 nM and 100 nM for MRCKα and MRCKβ, respectively. It blocks stress fiber formation and induces apoptosis, making it a valuable compound for cancer research.

Cotosudil is a ROCK kinase inhibitor that can be used in research related to glaucoma and ocular hypertension. It functions by reducing intraocular pressure through modulation of aqueous humor outflow.

THK01 is a potent and selective ROCK2 inhibitor, with IC₅₀ values of 5.7 nM for ROCK2 and 923 nM for ROCK1. It inhibits breast cancer metastasis by targeting the ROCK2–STAT3 signaling pathway and is suitable for research in breast cancer.

HSD1590 is a potent inhibitor of Rho-associated protein kinases, with IC₅₀ values of 1.22 nM for ROCK1 and 0.51 nM for ROCK2. It exhibits strong binding affinity to ROCK isoforms (K\_d < 2 nM) and demonstrates low cytotoxicity, making it suitable for further research applications.

CRT0066854 is a potent and selective inhibitor of atypical protein kinase C (PKC) isoenzymes. It inhibits full-length PKCι, PKCζ, and ROCK-II with IC₅₀ values of 132 nM, 639 nM, and 620 nM, respectively.

AS1892802 is a potent, orally active, and highly selective inhibitor of Rho-associated kinase (ROCK). It exhibits a rapid onset of antinociceptive effect, comparable to that of Tramadol and Diclofenac. Unlike traditional analgesics, AS1892802 does not induce gastric irritation or abnormal behavior, making it a promising candidate for research in the treatment of severe osteoarthritis pain.

PF-4950834 is a potent, selective, and orally bioavailable ATP-competitive inhibitor of Rho-associated kinases, with IC₅₀ values of 8.35 nM for ROCK2 and 33.12 nM for ROCK1. It effectively inhibits neutrophil migration and is suitable for research on inflammation and immune cell regulation.

OXA-06 hydrochloride is an ATP-competitive inhibitor of Rho-associated protein kinase (ROCK) that suppresses anchorage-dependent growth and invasion of non-small cell lung cancer (NSCLC) cell lines. It inhibits cofilin phosphorylation without inducing apoptosis.

Hispidin is a phenolic compound and protein kinase C (PKC) inhibitor derived from *Phellinus linteus*. It exhibits strong antioxidant, anticancer, antidiabetic, and anti-dementia activities, making it a promising candidate for research in various disease models.

IDE2 is a cell-permeable small molecule that promotes definitive endoderm formation in both mouse and human embryonic stem cells (ESCs) through activation of the TGF-β signaling pathway.

Lobeglitazone sulfate is a novel thiazolidinedione and an orally active agonist of peroxisome proliferator-activated receptors (PPARs), with EC50 values of 137.4 nM for PPARγ and 546.3 nM for PPARα. It also acts as an inhibitor of the ERK/JNK/Smad/NF-κB signaling pathways. Lobeglitazone sulfate exhibits anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic activities, supporting its potential in the treatment of metabolic and inflammatory diseases.

Gardenin A is an orally active synthetic polymethoxyflavone (PMF) analogue with neurotrophic properties, promoting neurite outgrowth and neuronal differentiation. It enhances neuritogenesis through activation of the MAPK/ERK, PKC, and PKA pathways, independent of TrkA and CREB signaling. Additionally, Gardenin A exhibits sedative, anxiolytic, antidepressant, and anticonvulsant effects, making it a promising compound for neurological and neuropsychiatric research.

Gondoic acid (cis-11-Eicosenoic acid) is a monounsaturated long-chain fatty acid found in various plant oils and nuts. It exhibits anti-inflammatory activity by reducing reactive oxygen species (ROS) production and inhibiting the PKCθ/ERK/STAT3 signaling pathway. Gondoic acid is also utilized as a raw material in medical applications and as a moisturizing agent in cosmetic formulations.

Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions.

MY-673 is a colchicine binding site inhibitor (CBSI) that disrupts microtubule dynamics by inhibiting tubulin polymerization. In addition to its antimitotic effects, MY-673 suppresses the ERK signaling pathway, which leads to modulation of SMAD4 protein expression within the TGF-β/SMAD signaling axis. These combined actions result in potent inhibition of cancer cell proliferation and migration, and the induction of apoptosis, both in vitro and in vivo. MY-673 holds promise as a therapeutic candidate for targeting cancers driven by aberrant microtubule dynamics and dysregulated TGF-β/ERK signaling.

4′-Demethylnobiletin is a bioactive metabolite derived from citrus polymethoxyflavones, known for its neuroprotective and cognition-enhancing properties. It activates the PKA/ERK/CREB signaling pathway and enhances CRE (cAMP response element)-mediated transcription in hippocampal neurons, processes essential for synaptic plasticity and memory formation. Additionally, 4′-Demethylnobiletin reverses memory impairment caused by NMDA receptor antagonism by stimulating ERK signaling, highlighting its therapeutic potential for neurodegenerative diseases and cognitive dysfunction.

HA-1004 is a selective and multifunctional inhibitor of cyclic nucleotide-dependent protein kinases, including protein kinase A (PKA) and cyclic GMP-dependent protein kinase (PKG). It regulates key second messenger pathways involving cyclic AMP and cyclic GMP and has broad pharmacological effects. HA-1004 inhibits lipolysis and induces vascular smooth muscle relaxation, acting as a vasodilator. It also functions as a calcium antagonist, contributing to its ability to suppress contraction in rabbit aortic strips. In neurological models, HA-1004 has been shown to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models, suggesting potential relevance in addiction and neurochemical regulation. Its diverse actions make it a valuable tool for studying cardiovascular, metabolic, and neurobiological processes.

ML192 is a selective antagonist of G protein-coupled receptor 55 (GPR55), effectively inhibiting GPR55-mediated signaling pathways. It blocks β-arrestin trafficking, suppresses ERK1/2 phosphorylation, and prevents PKCβII translocation, thereby interfering with downstream cellular responses. ML192 is a valuable tool for studying the physiological and pathological roles of GPR55 in processes such as inflammation, pain, cancer, and metabolic regulation.

SY-LB-35 is a potent agonist of bone morphogenetic protein (BMP) receptors, capable of activating both canonical and non-canonical signaling pathways. In the C2C12 myoblast cell line, SY-LB-35 significantly enhances cell proliferation and viability, promoting cell cycle progression by increasing the proportion of cells in the S and G2/M phases. Mechanistically, it activates the canonical Smad pathway as well as non-canonical PI3K/Akt, ERK, p38, and JNK signaling cascades. These properties make SY-LB-35 a valuable tool for studying BMP-related cellular processes and a potential therapeutic candidate for tissue regeneration and muscle repair.

Akt1&PKA-IN-2 (Compound R-29) is a AKT1 and PKA inhibitor with selectivity for CDK2, with IC50 values of 0.007 and 0.01 μM, respectively. Akt1&PKA-IN-2 is applicable for cancer research.

Akt1&PKA-IN-1 is a potent dual inhibitor targeting both Akt and Protein Kinase A (PKA), exhibiting IC50 values of 0.03 μM for PKAα and 0.11 μM for Akt, with a higher IC50 of 9.8 μM for cyclin-dependent kinase 2 (CDK2). This compound demonstrates selective inhibition of CDK2, making it a valuable tool for research in cancer biology and cellular signaling pathways. Akt1&PKA-IN-1 is useful for studying the regulatory role of these kinases in cellular processes and potential therapeutic applications.

H-9 Dihydrochloride is a potent inhibitor of protein kinase A (PKA), effectively modulating signaling pathways involved in various biological functions. At a concentration of 10 μM, it significantly diminishes the excitatory response to 5-hydroxytryptamine (5-HT) and exhibits direct effects on pharyngeal activity. Additionally, H-9 Dihydrochloride inhibits signal transduction and cell growth in epidermal growth factor (EGF)-dependent epithelial cell lines, making it a valuable tool for research in cellular signaling and growth regulation.

Netarsudil hydrochloride is a selective inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). It effectively lowers intraocular pressure by promoting relaxation of trabecular meshwork cells and dilation of episcleral veins, enhancing aqueous humor outflow while simultaneously reducing its production. This compound is primarily utilized in research related to ocular hypertension and primary open-angle glaucoma.

Metadoxine is a potent inhibitor of protein kinase A (PKA), specifically disrupting the PKA-cAMP response element binding protein (CREB) pathway. This compound is effective in blocking adipocyte differentiation, making it valuable for research into metabolic disorders and obesity-related pathways. Its ability to modulate PKA activity demonstrates potential applications in studying cellular signaling and metabolic regulation.

NSC668394 is a selective inhibitor of ezrin phosphorylation at threonine 567, exhibiting a Kd of 12.59 μM. This compound effectively prevents the phosphorylation of ezrin induced by PKCΙ through direct binding, thereby interfering with key signaling pathways. NSC668394 is primarily utilized in research focused on inhibiting tumor metastasis and studying ezrin's role in cancer progression.

R59949 is a pan diacylglycerol kinase (DGK) inhibitor that exhibits an IC50 of 300 nM. This compound effectively inhibits the activity of type I DGK α and γ, while also moderately reducing the activity of type II DGK θ and κ. Additionally, R59949 promotes the activation of protein kinase C (PKC) by increasing endogenous diacylglycerol levels. It serves as a valuable tool for studying DGK and PKC signaling pathways in various biological contexts.

PKN1/2-IN-1 is a selective inhibitor of protein kinase N isoforms 1 and 2 (PKN1 and PKN2), demonstrating IC50 values of 16 nM and 210 nM, respectively, along with Ki values of 8 nM and 108 nM. This compound effectively permeates cell membranes and shows significant binding affinity for PKN2, as indicated by NanoBRET assays (IC50 = 2.1 μM). PKN1/2-IN-1 is valuable for investigating physiological processes, particularly in research focused on tumor cell migration and related signaling pathways.

1-Oleoyl-2-acetyl-sn-glycerol is a cell-permeable diacylglycerol (DAG) analog that activates Protein Kinase C (PKC) as its primary target. It is known to induce specific Ca2+ influx through TRPC channels, enhance superoxide production in human neutrophils, and promote the synthesis of phosphatidylinositol 4-phosphate in intact human platelets. Additionally, 1-Oleoyl-2-acetyl-sn-glycerol has been demonstrated to stimulate the proliferation of ascites tumor cells, making it useful for various biochemical and pharmacological studies.

CC-90005 is a potent and selective inhibitor of protein kinase C-θ (PKC-θ), exhibiting an IC50 of 8 nM. This compound demonstrates considerable selectivity for PKC-θ over PKC-δ, with an IC50 of 4440 nM. CC-90005 effectively inhibits T cell activation by downregulating IL-2 expression, making it a valuable tool for research in immunology and T cell signaling pathways.

Psychosine, or galactosylsphingosine, serves as a substrate for the galactocerebrosidase (GALC) enzyme and is recognized as a potential biomarker for Krabbe disease. This cytotoxic lipid is known to induce apoptosis, leading to cell death in various cell types, particularly oligodendrocytes, which are significant in the context of globoid cell leukodystrophy (GLD). Additionally, psychosine acts as an inhibitor of protein kinase C (PKC), further emphasizing its role in cellular signaling pathways and potential applications in neurological research.

ZIP is a selective peptide inhibitor of Protein Kinase M zeta (PKMζ), which plays a crucial role in synaptic plasticity and memory processes. This compound effectively impairs morphine-induced conditioned place preference, making it a valuable tool for studying addiction and the molecular mechanisms underlying memory formation. Research applications include investigating the role of PKMζ in memory reinforcement and the modulation of synaptic strength.

Procyanidin A1 is a potent inhibitor of protein kinase C (PKC) activity, effectively blocking degranulation processes in response to PKC activation and calcium influx in RBL-213 mast cells. This compound exhibits significant antiallergic properties, making it valuable for research applications focused on allergic responses and related signaling pathways. Its ability to modulate cellular activities makes Procyanidin A1 a useful tool in studying allergic mechanisms and developing therapeutic strategies.

Myelin Basic Protein (MHP4-14) serves as a specific substrate for protein kinase C (PKC), demonstrating a Km of 7 μM. This synthetic peptide, derived from residues 4-14 of myelin basic protein, is not phosphorylated by various other kinases, including cyclic AMP-dependent protein kinase and casein kinases I and II. It is highly effective for studying PKC activity in crude tissue extracts, providing a low background and reliable results in biochemical assays.

N-Desmethyltamoxifen hydrochloride is a prominent inhibitor of protein kinase C (PKC). As the primary metabolite of tamoxifen, it exhibits ten-fold greater potency against PKC compared to its predecessor. Additionally, this compound effectively regulates ceramide metabolism in human acute myeloid leukemia (AML) cells by limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation. Its properties make it valuable for research in cancer biology and metabolic regulation.

1-Stearoyl-2-arachidonoyl-sn-glycerol is a diacylglycerol (DAG) that serves as a potent activator of protein kinase C (PKC). This compound exhibits significant biological activity by enhancing the activity of nonselective cation channels (NSCC). It is commonly utilized in research applications aimed at elucidating PKC-related signaling pathways and assessing the physiological roles of DAG in cellular processes.

H-7 dihydrochloride is a potent inhibitor of protein kinase C (PKC), effectively blocking its activity. At a concentration of 100 μM, H-7 dihydrochloride completely inhibits ornithine decarboxylase induction stimulated by both TPA (12-O-tetradecanoylphorbol-13-acetate) and phospholipase C. This reagent is widely utilized in research to investigate PKC-related signaling pathways and its role in cellular processes such as proliferation and differentiation.

SC-10 is a potent activator of protein kinase C (PKC), specifically targeting its catalytic activity. This compound enhances PKC signaling pathways, facilitating various cellular processes. SC-10 is widely employed in research applications focusing on cell signaling, cancer biology, and neurobiology, where it helps to elucidate the roles of PKC in cellular growth, differentiation, and apoptosis.

Cercosporin is a potent protein kinase C (PKC) inhibitor derived from the plant pathogen Pseudocercosporella capsellae. This compound acts as an effective photosensitizer due to its short activation wavelength, making it particularly suitable for superficial photodynamic therapy (PDT) applications where avoiding tissue perforation is crucial. With an IC50 ranging from 0.6 to 1.3 μM, cercosporin showcases significant biological activity in modulating cellular signaling pathways, contributing to its potential utility in cancer research and therapeutic development.

Aurothiomalate sodium is a selective inhibitor of the oncogenic protein kinase C iota (PKCι), demonstrating significant potential in cancer research. This compound effectively inhibits tumor cell proliferation while having minimal effects on cell apoptosis, highlighting its unique mechanism of action. Additionally, Aurothiomalate sodium acts as a potent inhibitor of thioredoxin reductase (TrxR) and possesses anti-tumor properties, making it a valuable tool for investigating signaling pathways involved in cancer biology and therapeutic responses. Its anti-rheumatic properties further extend its relevance in related biomedical studies.

PS432 is a selective protein kinase C (PKC) inhibitor, demonstrating IC50 values of 16.9 μM for PKCι and 18.5 μM for PKCζ. This compound effectively reduces the proliferation of non-small cell lung cancer (NSCLC) cells and inhibits tumor growth in mouse xenograft models. It serves as a valuable tool for research applications targeting PKC signaling pathways in cancer biology.

Protein kinase inhibitor H-7 is a selective inhibitor of protein kinase C (PKC) and cyclic nucleotide-dependent protein kinase, exhibiting a Ki of 6 μM for PKC. This compound has been widely used in research to investigate the role of PKC in various cellular processes, including signal transduction and cell proliferation. Additionally, H-7 serves as a valuable tool in studies focused on the modulation of kinases and their associated pathways.

Aprinocarsen sodium is a specific antisense oligonucleotide that targets protein kinase C-alpha (PKC-α), functioning as a potent inhibitor. This 20-mer oligonucleotide modulates cellular processes such as differentiation and proliferation. In vivo studies demonstrate its ability to inhibit the growth of human tumor cell lines in nude mice, highlighting its potential utility as a chemotherapeutic agent in the treatment of various human cancers.

Bisindolylmaleimide II is a potent inhibitor of Protein Kinase C (PKC) isoforms, serving as a valuable tool for dissecting PKC-related signaling pathways. Its inhibitory effect on all PKC subtypes makes it useful in studies investigating cellular processes such as proliferation, differentiation, and apoptosis. This compound is widely applied in research aiming to elucidate the role of PKC in various disease models, including cancer and neurodegenerative disorders.

SBI-0087702 is a selective inhibitor of ATF2, primarily targeting its phosphorylation at Thr52 by PKCε. This reagent induces the translocation of ATF2 to the mitochondria in melanoma cells, leading to enhanced apoptosis through the disruption of mitochondrial membrane integrity. Additionally, SBI-0087702 demonstrates significant effects on reducing both the growth and motility of melanoma cells, making it a valuable compound for research into cancer biology and therapeutic applications.

Z-Arg-SBzl is a specific substrate for both bovine and activated human protein C. It effectively facilitates the study of protein C activity and its role in coagulation processes. This compound is valuable for research applications focused on thrombosis and hemostasis, enabling the development of assays to investigate the regulatory mechanisms of blood coagulation.

Myelin basic protein, MBP (68-86), is a peptide derived from the 68th to 86th amino acid residues of the myelin basic protein sequence. This peptide functions as an autoantigen, initiating immune responses that can lead to the destruction of myelin. MBP (68-86) is utilized in the experimental autoimmune encephalomyelitis (EAE) animal model, making it a valuable tool for investigating the immunological mechanisms involved in multiple sclerosis (MS).

Bacopaside I is a selective AQP1 inhibitor and protein kinase C (PKC) modulator with notable neuroprotective and anticancer properties. It specifically inhibits the water channel and cGMP-gated ion channel activities of AQP1, thereby reducing the migration of AQP1-expressing colon cancer cells. Additionally, Bacopaside I activates the Akt pathway through PI3K interaction, inhibits MAO-A, and mitigates neuron necrosis and apoptosis due to oxygen-glucose deprivation, while lowering oxidative stress and modulating neuroreceptor expression. This compound is relevant for research in colon cancer, breast cancer, vascular dementia, cerebral ischemia, and associated diseases.

Protein Kinase Inhibitor 9 is a potent inhibitor of serine/threonine and tyrosine kinase activity. It demonstrates significant anti-proliferative effects, making it valuable for cancer research and the study of hyperproliferative disorders. Additionally, this compound can be applied in investigations related to rheumatoid arthritis, immune system dysfunctions, transplant rejections, and inflammatory disorders.

Bisindolylmaleimide III is a selective inhibitor of protein kinase C alpha (PKCα), effectively disrupting its activity. This compound selectively engages with PKCα or ribosomal S6 protein kinase 1 following their activation, making it a valuable tool in dissecting PKC-related signaling pathways. It is widely utilized in cancer research and studies investigating cell growth and differentiation.

PKCTheta-IN-2 is a highly potent and selective inhibitor of protein kinase C theta (PKCθ) with an IC50 value of 0.25 nM. This compound demonstrates exceptional selectivity for PKCθ over more than 30 other kinases within the PKC subfamily. PKCTheta-IN-2 effectively inhibits interleukin-2 (IL-2) production in murine models, exhibiting an IC50 of 682 nM. Its use in research is particularly relevant for studies involving T cell signaling and autoimmune disorders.